Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Inflection Resources Presents Australian Copper-Gold Exploration Strategy

Inflection Resources Presents Australian Copper-Gold Exploration Strategy

BitgetBitget2026/10/20 19:59
  • Inflection Resources highlighted ongoing Phase II exploration at its Trangie and Nyngan projects under its AngloGold Ashanti partnership.
  • AngloGold is fully funding approximately 17,500 meters of drilling across about 98 holes at Trangie.
  • Phase II requires AUD 7 million in spending per project for AngloGold to earn a 51% interest in each.
  • Cumulative earn-in spending of AUD 64 million allows AngloGold to earn 65% in each project.
  • AngloGold can increase its interest to 75% by completing a qualifying prefeasibility study and issuing Inflection a royalty.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflection Resources Ltd. published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Profit surges; amid concerns over U.S. surgical volume, JPMorgan maintains "Overweight" on Intuitive Surgical (ISRG.US) and raises target price to $475

Intuitive Surgical (ISRG.US), the global leader in surgical robots, released its Q3 2026 earnings report on October 20 (U.S. Eastern Time). On the same day, JPMorgan published a research report, maintaining an "Overweight" rating on the stock.

智通财经•2026/10/21 07:13

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) sets IPO price at $16-18 per share, plans to raise $250 million

Lycia Therapeutics announced the terms of its initial public offering (IPO) on Tuesday.

智通财经•2026/10/21 07:06